Live Breaking News & Updates on Meeting of the oncologic drugs advisory committee

Stay informed with the latest breaking news from Meeting of the oncologic drugs advisory committee on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Meeting of the oncologic drugs advisory committee and stay connected to the pulse of your community

ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

United-states , America , Kennethc-anderson , Johnson , Oncologic-drugs-advisory-committee , Bristol-myers-squibb , Meeting-of-the-oncologic-drugs-advisory-committee , Drugs-advisory-committee , D , Dana-farber-cancer-institute- , Odac

Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.

New-york , United-states , Saadz-usmani , Johnson , Oncologic-drugs-advisory-committee , Janssen-biotech-inc , Meeting-of-the-oncologic-drugs-advisory-committee , Drugs-advisory-committee , Myeloma-service , Memorial-sloan-kettering-cancer-center ,

Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS

Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.

New-york , United-states , Sunil-iyer , Oncologic-drugs-advisory-committee , Meeting-of-the-oncologic-drugs-advisory-committee , Columbia-university-irving-medical-center , International-prognostic-scoring-system , Drugs-advisory-committee , Science-summit , New-york-city , D , Mds

FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL

The FDA has approved polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for certain patients with treatment-naive diffuse large B-cell lymphoma.

Roche-polivy , Oncologic-drugs-advisory-committee , International-prognostic-index , Youtube , Meeting-of-the-oncologic-drugs-advisory-committee , Drugs-advisory-committee , Pacific-lymphoma-conference , Polatuzumab-vedotin-piiq , Diffuse-largeb-cell-lymphoma , Dlbcl ,